MedTrace Logo

162 mg of Aspirin for Prevention of Preeclampsia

NCT05221164 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2022-02-02

No results posted yet for this study

Summary

This is a study to assess if 162 mg of aspirin will decrease rates of preeclampsia in pregnant patients compared to 81 mg of aspirin.

Conditions

Interventions

DRUG

Aspirin 162 mg

Daily aspirin 162 mg during pregnancy to prevent preeclampsia

Sponsors & Collaborators

  • University of Illinois College of Medicine at Peoria

    collaborator OTHER

  • UICOM Peoria Family Medicine Residency

    collaborator UNKNOWN

  • Methodist Medical Center of Illinois

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-07-06
Primary Completion
2022-06-09
Completion
2022-06-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05221164 on ClinicalTrials.gov